Prostatic Neoplasm Clinical Trial
Official title:
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells. Suramin has shown effectiveness as a treatment for hormonally refractory prostate carcinoma. Survival was less in patients with high rather than low circulating androgen levels. Thus, suramin might slow the emergence of hormone refractory tumor cells while combined androgen ablation may maximize the effectiveness of suramin. In this trial, we will pilot this concept.
The purpose of this study is to assess the potential for combined androgen blockage (Leuprolide and Flutamide), given with suramin (a growth factor inhibitor) to improve the clinical outcome(s) in a cohort of patients with bulky metastatic prostate cancer. Combined androgen blockage is currently the standard of care for such individuals. Suramin has shown reproducible activity in individuals with androgen independent disease. Since these two approaches are independent of one another - on the molecular level, and in clinical results - it is hoped that the combination of these two approaches will result in improved response rates and in improved survival. ;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03982095 -
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
|
||
Recruiting |
NCT05667636 -
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
|
Phase 2 | |
Terminated |
NCT01996696 -
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
|
Phase 2 | |
Completed |
NCT01431391 -
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT03289130 -
Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
|
||
Recruiting |
NCT04462926 -
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
|
N/A | |
Completed |
NCT00001446 -
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
|
Phase 2 | |
Completed |
NCT02729103 -
Treatment Patterns in Metastatic Prostate Cancer
|
N/A | |
Completed |
NCT00956228 -
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00247312 -
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
|
Phase 3 | |
Completed |
NCT00126854 -
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
|
N/A | |
Completed |
NCT00174863 -
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
|
Phase 2 | |
Terminated |
NCT04221828 -
Trial of NanoPac Focal Therapy for Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03935282 -
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
|
N/A | |
Completed |
NCT03693742 -
MSG Use With 18F-DCFPyL PET/CT Imaging
|
N/A | |
Recruiting |
NCT06236789 -
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
|
||
Completed |
NCT02966535 -
The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial
|
N/A | |
Completed |
NCT02977143 -
Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery
|
N/A | |
Completed |
NCT00252460 -
CT/MRI Co-registration Prostate Cancer
|
Phase 1 | |
Completed |
NCT04398173 -
Detection Rate of Prostate Cancer in Men Undergoing MRI
|